Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADXN
stocks logo

ADXN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2024Q4
FY2025Q2
110.00K
-66.57%
--
--
150.00K
-2.25%
--
--
200.00K
+73.49%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Addex Therapeutics Ltd (ADXN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 7.86%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+7.86%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Addex Therapeutics Ltd (ADXN.O) is 0.00, compared to its 5-year average forward P/E of -1.42. For a more detailed relative valuation and DCF analysis to assess Addex Therapeutics Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.42
Current PE
0.00
Overvalued PE
-0.20
Undervalued PE
-2.63

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.00
Current EV/EBITDA
-1.21
Overvalued EV/EBITDA
-0.20
Undervalued EV/EBITDA
-1.80

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
17.30
Current PS
4.08
Overvalued PS
39.89
Undervalued PS
-5.29
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ADXN News & Events

Events Timeline

(ET)
2025-06-06
05:06:10
Addex reports anti-tussive activity of GABAB positive allosteric modulator
select
2025-04-30 (ET)
2025-04-30
05:39:19
Addex Therapeutics enters collaboration with Sinntaxis AB
select
2025-04-17 (ET)
2025-04-17
05:21:07
Addex Therapeutics regains rights to ADX71149
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
12-04Globenewswire
PinnedAddex Reports Q3 2025 Financial Results with CHF 1.58M Net Loss
  • Revenue Decline: Addex reported Q3 2025 income of CHF 505,800, down CHF 80,000 year-over-year, primarily due to the completion of the R&D collaboration phase with Indivior, impacting revenue streams significantly.
  • R&D Expense Reduction: The company incurred R&D expenses of CHF 228,000 in Q3 2025, a slight increase from CHF 204,000 in the same quarter last year, indicating ongoing investment in the GABAB PAM chronic cough clinical candidate despite the completion of earlier phases.
  • Widening Net Loss: As of September 30, 2025, Addex's net loss reached CHF 1.577 million, an increase of CHF 49,000 from CHF 1.528 million in the prior year, primarily driven by increased losses from its investment in Neurosterix US Holdings LLC.
  • Cash Flow Situation: Cash and cash equivalents decreased to CHF 2.187 million as of September 30, 2025, down CHF 1.162 million from CHF 3.349 million a year earlier, reflecting cash outflow pressures from operational activities.
[object Object]
Preview
2.0
12-04Benzinga
UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading

  • UiPath Financial Results: UiPath Inc. shares rose 8.7% in pre-market trading after reporting third-quarter adjusted earnings of 16 cents per share and revenue of $411.11 million, both exceeding estimates.

  • Other Gainers: Several stocks saw significant pre-market gains, including Polyrizon Ltd (+158.1%), Nauticus Robotics, Inc (+34%), and Picard Medical, Inc (+22.3%), driven by positive news and developments.

  • Notable Losers: Virax Biolabs Group Ltd fell 16.2% after announcing a private placement, while Treasure Global Inc declined 13.3% following a reverse stock split and Nasdaq delisting notification.

  • Market Overview: The pre-market trading session showed a mix of gains and losses across various stocks, with some companies like Axogen, Inc and Hyster-Yale, Inc also experiencing notable increases.

[object Object]
Preview
9.5
12-01Globenewswire
Addex Therapeutics to Report Q3 2025 Financial Results on December 4
  • Financial Report Announcement: Addex Therapeutics will report its Q3 2025 financial results on December 4 at 16:00 CET, which is expected to provide crucial updates on the company's product pipeline, aiding investors and analysts in understanding its developmental trajectory.
  • Executive Update: CEO Tim Dyer and Head of Translational Science Mikhail Kalinichev will provide a business update during the teleconference, likely discussing the progress of Addex's lead drug candidate, dipraglurant, particularly its potential applications in brain injury recovery.
  • Investor Participation: Participants are required to register in advance to receive dial-in numbers and a personal PIN, ensuring a smooth conference call, which reflects the company's commitment to transparency and investor relations.
  • Market Positioning: Focused on developing small molecule allosteric modulators for neurological disorders, Addex's upcoming financial report will be closely watched for updates on its drug development and partnerships, indicating its strategic positioning in the biopharmaceutical market.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Addex Therapeutics Ltd (ADXN) stock price today?

The current price of ADXN is 8.3805 USD — it has decreased -6.79 % in the last trading day.

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s business?

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

arrow icon

What is the price predicton of ADXN Stock?

Wall Street analysts forecast ADXN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADXN is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s revenue for the last quarter?

Addex Therapeutics Ltd revenue for the last quarter amounts to 44.01K USD, decreased -65.48 % YoY.

arrow icon

What is Addex Therapeutics Ltd (ADXN)'s earnings per share (EPS) for the last quarter?

Addex Therapeutics Ltd. EPS for the last quarter amounts to -0.02 USD, decreased -114.29 % YoY.

arrow icon

What changes have occurred in the market's expectations for Addex Therapeutics Ltd (ADXN)'s fundamentals?

The market is revising No Change the revenue expectations for Addex Therapeutics Ltd (ADXN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 7.86%.
arrow icon

How many employees does Addex Therapeutics Ltd (ADXN). have?

Addex Therapeutics Ltd (ADXN) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Addex Therapeutics Ltd (ADXN) market cap?

Today ADXN has the market capitalization of 10.32M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free